hero section gradient
8 handpicked stocks

High Yielding Stocks

Looking for income from your investments? These carefully selected companies have historically paid substantial dividends compared to their share prices. Our analysts have handpicked these stocks for their dividend potential.

Author avatar

Han Tan | Market Analyst

Published on May 7

Your Basket's Financial Footprint

Summary of total market capitalisation and implications of large-cap concentration for the 'High Yielding Stocks' basket.

Key Takeaways for Investors:
  • Large‑cap dominance generally implies greater stability and lower volatility versus small‑cap, aligning returns with broad market trends.
  • Treat as a core, long‑term holding rather than a speculative trade; useful for portfolio stability and income exposure.
  • Expect steady, income‑oriented returns over time; unlikely to deliver rapid, explosive short‑term gains.
Total Market Cap
  • IEP: $4.69B

  • OXLC: $1.35B

  • AGNC: $10.78B

  • Other

About This Group of Stocks

1

Our Expert Thinking

These stocks offer attractive dividend yields relative to their current prices. From REITs and energy partnerships to financial services and shipping companies, they represent sectors that traditionally prioritize returning value to shareholders through regular dividend payments.

2

What You Need to Know

High-yield stocks can provide steady income, but they often come with higher risk profiles. These companies are currently undervalued compared to their historical dividend payments, suggesting potential value. Consider these as part of a balanced portfolio rather than your entire investment strategy.

3

Why These Stocks

We've selected companies across diverse sectors including REITs, natural resources, shipping, and financial services. Each has demonstrated a commitment to maintaining dividend payments, creating potential income opportunities for investors looking beyond just stock price appreciation.

Why You'll Want to Watch These Stocks

💰

Regular Income Potential

These high-yield stocks can provide regular dividend payments, creating a steady income stream that many investors find attractive compared to growth-only stocks.

🔍

Currently Undervalued

Our analysts believe these stocks may be undervalued relative to their dividend history, potentially offering both income and price appreciation if markets recognize their value.

🌍

Diverse Sector Exposure

From real estate and energy to shipping and financial services, this collection offers exposure to multiple dividend-focused sectors in a single convenient group.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions